following a full submission:
delgocitinib (Anzupgo®) is accepted for use within NHSScotland.
Indication under review: Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.
In two phase III studies, delgocitinib significantly improved treatment success at 16 weeks, based on the Investigator’s Global Assessment for Chronic Hand Eczema, in patients with moderate to severe CHE, compared with vehicle cream. In a third phase III trial, delgocitinib also led to a significantly greater reduction in the Hand Eczema Severity Index score than alitretinoin in patients with severe CHE at week 12.
Medicine details
- Medicine name:
- delgocitinib (Anzupgo)
- SMC ID:
- SMC2817
- Indication:
Treatment of moderate to severe chronic hand eczema (CHE) in adults for whom topical corticosteroids (TCS) are inadequate or inappropriate.
- Pharmaceutical company
- LEO Pharma
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 December 2025